Rapafusyn Pharmaceuticals
Rapafusyn is pioneering RapaGluesTM, a unique modality of non-degrading molecular glues designed to target previously intractable proteins. The company's mission is to develop transformative therapies for patients with limited or no treatment options, focusing on challenging intracellular proteins using its proprietary platform. Their lead program targets Acute Kidney Injury (AKI), a severe complication with no current approved therapies, by inhibiting ENT1 to preserve extracellular adenosine levels and mitigate ischemia/reperfusion injury. The company is supported by a team of experienced drug development leaders and is actively engaged in partnerships and collaborations to expand its innovative drug discovery efforts.
Industries
Nr. of Employees
small (1-50)
Rapafusyn Pharmaceuticals
Patents
Products
Selective ENT1 inhibitor — clinical development candidate for prevention of ischemia/reperfusion-driven acute kidney injury
A potent and selective inhibitor of equilibrative nucleoside transporter 1 developed to preserve extracellular adenosine and mitigate ischemia/reperfusion-driven renal injury; supported by preclinical efficacy in relevant models and advanced toward clinical development.
RAP-0001
A first-in-class clinical candidate and highly potent and selective ENT1 inhibitor with demonstrated preclinical efficacy in preventing ischemia/reperfusion injury during cardiac surgery and other clinical settings.
RapaGlues
Proprietary modality comprised of highly selective, non-degrading macrocyclic molecular glues that precisely modulate hard-to-drug intracellular and transmembrane targets.
ENT1 Inhibitor (SLC for Acute Kidney Injury)
An internal pipeline program targeting ENT1 for the treatment of acute kidney injury.
IMM-002 (TNFR1 Specific PPI for I&I)
An internal immunology and inflammation pipeline program targeting TNFR1 specific PPI.
IMM-003 (TNFR1 Specific PPI for I&I)
An internal immunology and inflammation pipeline program targeting TNFR1 specific PPI.
Selective ENT1 inhibitor — clinical development candidate for prevention of ischemia/reperfusion-driven acute kidney injury
A potent and selective inhibitor of equilibrative nucleoside transporter 1 developed to preserve extracellular adenosine and mitigate ischemia/reperfusion-driven renal injury; supported by preclinical efficacy in relevant models and advanced toward clinical development.
RAP-0001
A first-in-class clinical candidate and highly potent and selective ENT1 inhibitor with demonstrated preclinical efficacy in preventing ischemia/reperfusion injury during cardiac surgery and other clinical settings.
RapaGlues
Proprietary modality comprised of highly selective, non-degrading macrocyclic molecular glues that precisely modulate hard-to-drug intracellular and transmembrane targets.
ENT1 Inhibitor (SLC for Acute Kidney Injury)
An internal pipeline program targeting ENT1 for the treatment of acute kidney injury.
IMM-002 (TNFR1 Specific PPI for I&I)
An internal immunology and inflammation pipeline program targeting TNFR1 specific PPI.
IMM-003 (TNFR1 Specific PPI for I&I)
An internal immunology and inflammation pipeline program targeting TNFR1 specific PPI.
Services
Collaborative research and partnership arrangements to apply the integrated discovery platform for target discovery, hit identification and lead generation.
Structuring strategic collaborations, licensing agreements and accelerator engagements to advance programs and secure external support.
Collaborative research and partnership arrangements to apply the integrated discovery platform for target discovery, hit identification and lead generation.
Structuring strategic collaborations, licensing agreements and accelerator engagements to advance programs and secure external support.
Expertise Areas
- Induced-proximity small-molecule therapeutics (non-degrading)
- Macrocycle library design and medicinal chemistry
- DNA-encoded library discovery and screening
- Target identification and validation for intracellular and transporter proteins
Key Technologies
- Induced-proximity small-molecule design
- Macrocycle synthesis and screening
- DNA-encoded libraries (DEL)
- Arrayed small-molecule microarrays
News & Updates
Rick Ewing received the 2023 Edison Patent Award recognizing his work in innovation with tangible commercial impact, specifically for the patent on Phosphorous (V)-Based Reagents.
Rick Ewing was honored with the 2023 ACS Philadelphia Section Award for his distinguished career and contributions to chemical sciences.
Rick Ewing received the 2023 Edison Patent Award recognizing his work in innovation with tangible commercial impact, specifically for the patent on Phosphorous (V)-Based Reagents.
Rick Ewing was honored with the 2023 ACS Philadelphia Section Award for his distinguished career and contributions to chemical sciences.